MDxHealth Notice of Financial Year 2016 Results

Conference call for analysts and investors to be held on 23 February 2017 at 15:00 CET

IRVINE, CA, and HERSTAL, BELGIUM - February 9, 2017 - MDxHealth SA (Euronext: MDXH.BR) or the "Company" today announced that it will release its full year results for the financial year ended 31 December 2016 on Thursday 23 February 2017.

Dr. Jan Groen, Chief Executive Officer and Jean-Marc Roelandt, Chief Financial Officer, will host a conference call on the day of the results at 15:00 CET / 14:00 GMT / 06:00 PT. The call will be conducted in English and a replay will be available for 30 days.

To access the conference call, please dial one of the appropriate numbers below quoting the conference ID 69886101.

Belgium:                      +32 (0)81 70 00 61The Netherlands         +31 (0)8000 235 091UK:                              +44 (0)1452 55 55 66US:                              +1 (0)8669 669 439

The presentation will be made available on the Investors section of the MDxHealth website shortly before the call and can be accessed at: http://mdxhealth.com/investors.

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled start timing.

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.

For more information: 

Dr. Jan Groen, CEO MDxHealth US: +1 949 812 6979 BE: +32 4 364 20 70 [email protected]   Jean-Marc Roelandt, CFOMDxHealthUS: +1 949 812 6979 BE: +32 4 364 20 70 [email protected]

Consilium Strategic Communications (IR & PR)Amber Fennell, Chris Welsh & Hendrik Thys UK: +44 20 3709 5701US: +1 917 322 2571 (Rx Communications Group LLC)[email protected]

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/48f3c927-9290-4ad9-87bd-44a689dc1a43

Source: MDxHealth

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• CSPi to Announce Fiscal Third Quarter Results on August 14, 2026
• Muncy Columbia Financial Corporation Declares Dividend
• NFL Betting Handle to Hit Record $32.3B as Prediction Markets Near $37B